Compass Therapeutics
Quarterly Financials
| Values in thousands | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
Gross Profit | -367 | |||
EBITDA | -21,066 | -17,602 | -16,215 | -11,774 |
EBIT | -17,966 | -16,574 | -12,239 | |
Net Income | -19,881 | -16,633 | -15,033 | -10,481 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Free Cash Flow | -11,832 | -13,226 | -9,162 | -11,095 |
Cash | 22,856 | 41,048 | 43,483 | 36,801 |
Basic Shares | 138,282 | 138,236 | 136,627 | 137,589 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $850 | $0 | $0 | $0 |
Gross Profit | 850 | -1,890 | -1,904 | -1,624 |
EBITDA | -54,872 | -48,473 | -37,391 | -29,611 |
EBIT | -56,625 | -50,363 | -39,295 | -31,235 |
Net Income | -49,375 | -42,494 | -36,795 | -82,551 |
Net Change In Cash | 850 | 0 | 0 | 0 |
Cost of Revenue | -109,568 | 97,175 | ||
Free Cash Flow | -44,899 | -40,648 | -34,337 | -21,234 |
Cash | 43,483 | 24,228 | 34,946 | 144,514 |
Basic Shares | 137,108 | 127,027 | 105,186 | 62,870 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-09-30 | $0 |
2025-06-30 | -$0.14 |
2025-03-31 | -$0.12 |
2024-12-31 | -$0.11 |
